Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Purity is an essential amino acid (EAA) nutritional supplement developed by Amino Co and currently being evaluated in collaboration with the University of Colorado, Denver. It is a proprietary blend of essential amino acids designed to stimulate protein synthesis and reduce hepatic fat accumulation. The product is being investigated in a Phase 3 clinical trial (AMINOS, NCT05935826) for its efficacy in treating non-alcoholic fatty liver disease (NAFLD) and obesity in adolescents. While Purity is already marketed as a dietary supplement for general health and wellness, the AMINOS study aims to establish its therapeutic role in improving liver fat content and metabolic health in pediatric populations with excess liver fat.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Purity.